Langerhans cell histiocytosis secondary prevention

Jump to navigation Jump to search

Langerhans cell histiocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Langerhans cell histiocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Langerhans cell histiocytosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Langerhans cell histiocytosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Langerhans cell histiocytosis secondary prevention

on Langerhans cell histiocytosis secondary prevention

Langerhans cell histiocytosis secondary prevention in the news

Blogs on Langerhans cell histiocytosis secondary prevention

Directions to Hospitals Treating Langerhans cell histiocytosis

Risk calculators and risk factors for Langerhans cell histiocytosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

  • Complications may include:
  • Diffuse interstitial pulmonary fibrosis
  • Spontaneous pneumothorax
  • Children may also develop:
  • Anemia caused by spreading of the tumors to the bone marrow
  • Diabetes insipidus
  • Lung problems that lead to lung failure
  • Problems with the pituitary gland that lead to growth failure

References


Template:WikiDoc Sources